Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026
Ascendis Pharma (Nasdaq: ASND) will report full year 2025 financial results and provide a business update on Wednesday, February 11, 2026 after U.S. market close.
Rhea-AI Summary
Ascendis Pharma (Nasdaq: ASND) will report full year 2025 financial results and provide a business update on Wednesday, February 11, 2026 after U.S. market close. A conference call and live webcast are scheduled for 4:30 p.m. ET, with replay available for 30 days on the investor website.
Details
News Market Reaction – ASND
On Feb 5, the first trading day after this news, ASND closed 1.07% below the previous close.
Data tracked by StockTitan Argus for the Feb 5 session.
Key Figures
- Full year reported
- 2025
- Company plans to report full year 2025 financial results
- Earnings date
- February 11, 2026
- Scheduled date to report full year 2025 results
- Results release timing
- After close
- Financial results to be released after U.S. market close
- Conference call time
- 4:30 p.m. ET
- Start time of earnings call and webcast on February 11, 2026
- Webcast replay period
- 30 days
- Replay available on Investors & News section of company website
Historical Context
-
2026 roadmap, commercial updates, and unaudited 2025 financial metrics.
-
Positive Week 52 COACH Phase 2 results in children with achondroplasia.
-
Plan to present business update at J.P. Morgan Healthcare Conference.
-
FDA classified filing as major amendment and extended PDUFA date.
-
Publication of positive ApproaCH pivotal trial data in JAMA Pediatrics.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
COPENHAGEN, Denmark, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report full year 2025 financial results and provide a business update on Wednesday, February 11, 2026, after the close of the U.S. financial markets. Ascendis Pharma also plans to host a conference call and live webcast on February 11, 2026, at 4:30 p.m. Eastern Time (ET) to discuss 2025 financial results.
Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. The link to the live webcast will also be available on the Investors & News section of the Ascendis Pharma website at https://investors.ascendispharma.com. A replay of the webcast will be available on this section of the Ascendis Pharma website shortly after the conclusion of the event for 30 days.
About Ascendis Pharma A/S
Ascendis Pharma is applying its innovative TransCon technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by its core values of Patients, Science, and Passion, Ascendis uses its TransCon technologies to create new and potentially best-in-class therapies. Ascendis is headquartered in Copenhagen, Denmark and has additional facilities in Europe and the United States. Please visit ascendispharma.com to learn more.
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis’ plan to report financial results, provide a business update and host a conference call and live webcast on a certain date, (ii) Ascendis’ ability to apply its TransCon technology platform to make a meaningful difference in patients’ lives and (iii) Ascendis’ use of TransCon to create new and potentially best-in-class therapies. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including, without limitation: dependence on third‑party manufacturers, distributors, and service providers for Ascendis’ products and product candidates; risks related to regulatory review and approval, including the possibility of delays, requests for additional data or analyses, restrictions or limitations on use, approval with labeling that is more limited than expected, or failure to obtain approval in the United States, European Union, or other jurisdictions; clinical development risks, including that results from ongoing or future trials may not confirm earlier data; unforeseen safety or efficacy findings in development programs or on‑market products; manufacturing, supply chain, quality, or logistics issues that could delay development or commercialization; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen research and development or selling, general and administrative expenses and other costs impacting Ascendis’ business generally; market acceptance, pricing, and reimbursement challenges, including payer coverage decisions and health technology assessments; competitive developments, including new or improved therapies; intellectual property protection, freedom‑to‑operate, and litigation risks; Ascendis’ ability to obtain additional funding, if needed, to support its business activities; cybersecurity, data privacy, and information technology disruptions; and the impact of international economic, political, legal, compliance, public health, and business factors, including tariffs, trade policies, currency fluctuations, and geopolitical events. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis’ business in general, see Ascendis’ Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on February 12, 2025, and Ascendis’ other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.
Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, and TransCon are trademarks owned by the Ascendis Pharma group. © February 2026 Ascendis Pharma A/S.
| Investor Contacts: | Media Contact: |
| Chad Fugere | Melinda Baker |
| Ascendis Pharma | Ascendis Pharma |
| ir@ascendispharma.com | media@ascendispharma.com |
| Patti Bank | |
| ICR Healthcare | |
| +1 (415) 513-1284 | |
| patti.bank@icrhealthcare.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.